Friday, 4 September 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 4, 2026

B&G Foods outlines $1.655B–$1.695B sales target for 2026 as portfolio transformation accelerates

View original at seekingalpha.com
B&G Foods outlines $1.655B–$1.695B sales target for 2026 as portfolio transformation accelerates Earnings Call Insights: B&G Foods (BGS) Q4 2025 MANAGEMENT VIEW * Kenneth Keller, President, CEO & Director, opened by announcing a major portfolio reshaping milestone, stating the divestiture of the Green Giant U.S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Company will spend very similar amount in 2026 on brand support as in 2025, with different portfolio allocation and probable increase in spending on a few brands

    80% confidence
  • Green Giant U.S. frozen business was not the right fit due to seasonal production, geographic complexity, and high working capital intensity

    80% confidence
  • The divestiture of Green Giant U.S. frozen business is the largest piece in portfolio transformation that should result in stronger focus, simplification, greater synergies and higher margins across core shelf-stable business lines

    80% confidence
  • Base business trends on remaining core Meals, Spices & Flavor Solutions and Specialty businesses expected to improve plus 0.4% versus last year

    80% confidence
  • Net result of divestitures and acquisition will deliver more focused portfolio expected to generate positive adjusted EBITDA growth, stronger cash flows, lower working capital intensity, reduced leverage and higher gross and adjusted EBITDA margins

    80% confidence
  • Company is moving towards leverage targets but not there yet

    80% confidence
  • Spices and seasonings has been pretty resilient and posting good numbers, part of gradual improvement in U.S. food retail consumption

    80% confidence
  • Company is on way to 4.5x to 5.5x long-term leverage target but still has more work to do

    80% confidence
  • Proceeds from divestitures would be used to fund new acquisitions

    80% confidence
  • Based on 2026 guidance, adjusted diluted earnings per share expected to be in range of $0.55 to $0.65

    80% confidence
  • 4% quarter-to-date base business growth attributed to both weather-driven baking staples demand and lapping last year's trade inventory reduction

    80% confidence
  • Q4 2025 generated $539.6 million in net sales, net loss of $15.2 million or $0.19 per diluted share, adjusted net income of $22.8 million or $0.28 per adjusted diluted share, $84.7 million in adjusted EBITDA and adjusted EBITDA as percentage of net sales of 15.7%

    80% confidence
  • Q4 base business net sales improved to down approximately 2.4% compared to down 2.7% in Q3

    80% confidence
  • Seneca co-pack agreement has cost-plus structure ensuring profitability

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com